Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Work
Year: 2014
Type: article
Abstract: Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatm... more
Source: New England Journal of Medicine
Authors Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg +23 more
Institutions Oregon Health & Science University, Duke Medical Center, Memorial Sloan Kettering Cancer Center, Cornell University, Institut Gustave Roussy +24 more
Cites: 27
Cited by: 2,737
Related to: 10
FWCI: 226.1
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze